抗抑郁新药沃替西汀  

A new antidepressant,vortioxetine

作　　者：范宁[1,2] 杨甫德[2] 

机构地区：[1]河北联合大学心理学院,唐山063009 [2]北京回龙观医院,北京100096

出　　处：《中国新药杂志》2014年第16期1847-1850,共4页Chinese Journal of New Drugs

摘　　要：沃替西汀(vortioxetine)是由Lundbeck和Takeda制药公司联合研发的强效五羟色胺再摄取抑制剂,主要用于成人抑郁症(MDD)的治疗。2013年9月30日美国食品药品管理局(FDA)正式批准该药上市。目前的临床研究证实它在抑郁症治疗上具有良好的有效性、安全性和耐受性。本文就该药的作用机制、药物代谢动力学、临床研究及安全性等做一综述。Vortioxetine is a potent serotonin reuptake inhibitor and mainly used in the therapy of MDD in adults, and it was developed and commercialized by Lundbeck and Takeda Pharmaceutical company. Vortioxetine received its first approval for MDD by the US FDA in September 30, 2013. A large number of clinical researches have confirmed that vortioxetine has good efficacy, safety and tolerability in the therapy of MDD. In this review, we summarized the mechanisms of antidepressant action, pharmacokinetic and pharmacodynamic studies, clinical trials and adverse effects of vortioxetine.

关 键 词：沃替西汀 五羟色胺再摄取抑制剂 抑郁 焦虑 

分 类 号：R971.43[医药卫生—药品]